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• Gastrointestinal symptoms are experienced by the majority of CF patients.  
• Oro-caecal transit time was 2 hours longer in CF than controls. 
• Absent postprandial drop in small bowel water suggests partial ileal 
obstruction.  





Cystic fibrosis (CF) is a multi-system genetic disorder affecting >72,000 people 
worldwide. Most CF patients experience gastrointestinal symptoms and can develop 
complications. However, the mechanisms of CF gut disease are not well understood. 
We evaluated gut function and transit in CF using magnetic resonance imaging 
(MRI). We hypothesised oro-caecal transit time (OCTT) is longer in CF; with lower 
small bowel water content (SBWC).   
Methods 
Twelve CF patients aged 12-40 years and 12 age and sex-matched controls 
underwent serial MRIs over 1 day with standardised meals. The primary endpoint 
was OCTT, assessed by the appearance of a food bolus in the caecum. Other 
measures included corrected SBWC and corrected colonic volume (both area under 
the curve, AUC), gastric half-emptying time and gastrointestinal symptoms.  
Results 
OCTT was longer in CF (CF 330 mins [270, >360] vs. controls 210 mins [173, 315], 
p=0.04), with no difference in gastric half-emptying times. Corrected SBWC was 
higher in CF (CF 62 L.min/m2 [36, 80] vs. controls 34 L.min/m2 [28, 41], p=0.021); 
minimal postprandial decrease between T240 and T300 (CF 13mL/m2 [-13, 57] vs. 
controls 102 mL/m2 [67, 108], p = 0.002) suggests impaired ileal emptying. Corrected 
colonic volumes were higher in CF (CF 186 L.min/m2 [167, 206] vs. controls 123 
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L.min/m2 [89, 146], p=0.012). There were no differences in gastrointestinal 
symptoms. 
Conclusions  
MRI provides novel insights into CF pathophysiology. Sub-clinical ileal obstruction 
may be more prevalent than previously thought. Gastrointestinal MRI shows promise 
as an investigational tool in CF.  
ClinicalTrials.gov NCT03566550 
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Cystic fibrosis (CF) is an autosomal recessive disorder, affecting over 72,000 people 
worldwide.1-3 The mutation with the highest prevalence is p.Phe508del and between 
85-90% of CF patients have at least one copy of this gene mutation.2,3 The mutation 
leads to a dysfunctional CF transmembrane conductance regulator (CFTR) protein 
which disrupts the passage of chloride ions and bicarbonate, causing increased 
viscosity of epithelial mucus. CFTR is expressed on many epithelia; including the 
gastrointestinal mucosa.1  
In 2018, a James Lind Alliance Priority Setting Partnership involving patients, their 
families and clinicians identified the relief of gastrointestinal symptoms as one of the 
top priorities for CF research.4  
Almost every individual with CF experiences gastrointestinal symptoms.5,6 Nearly 
half report constipation.7 The most severe gastrointestinal complication, distal 
intestinal obstruction syndrome (DIOS), is seen in 5% of patients annually.3 Efforts to 
describe comprehensively the burden of gastrointestinal symptoms in CF, such as 
the North American GALAXY study,8 have used questionnaires derived for use in 
functional bowel disorders such as the Patient Assessment of Constipation-
Symptoms (PAC-SYM).9 In the United Kingdom, use of the Gastrointestinal 
Symptoms Rating Scale (GSRS) has identified a high symptom burden in a large 
proportion of patients.5 A CF-specific questionnaire (CFAbd-Score) has also been 
derived and validated6,10. Such work describes the prevalence and severity of 
symptoms but does not inform understanding of the underlying mechanisms. 
The association between gastrointestinal mechanisms and symptoms in CF is not 
fully understood. It has been proposed that altered intestinal fluid secretions,11 
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dysmotility, dysbiosis and intestinal inflammation contribute to gut dysfunction.12 
Investigations to address this knowledge gap must avoid undue increase in the high 
procedural burden already experienced by CF patients. Endoscopy is invasive 
(although sometimes clinically indicated); radiation exposure should be limited as 
patients are already subject to chest radiographs and CT scans to monitor their 
chest disease; capsule technologies for physiological assessment are not approved 
for use in children. 
Magnetic Resonance Imaging (MRI) has been used in research to study gut function 
non-invasively for over 20 years. Validated MRI measures of gastric emptying,13 
small bowel water content (SBWC),14 oro-caecal transit time (OCTT),15 and colonic 
volumes16 have been applied to gut diseases such as irritable bowel syndrome,16 
inflammatory bowel disease and constipation.17  
Aims 
The aim of the of the Gut Imaging for Function and Transit in CF (GIFT-CF) study 
was to evaluate the feasibility and utility of MRI in assessing gut function and transit 
in CF patients. Our principal hypothesis was: OCTT is slower in CF patients based 
on previous report.18 Our secondary hypotheses were CF patients have:  
• less SBWC than controls due to CFTR dysfunction; 
• larger colonic volumes because of the prevalence of constipation in CF;  
• symptoms correlating with underlying physiological abnormalities. 
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Methods  
We conducted a prospective study, using MRI to compare the postprandial changes 
in gut function and transit in people with and without CF.  
Study population  
All participants with CF were homozygous for the p.Phe508del mutation and aged 
between 12 and 40 years. CF patients were recruited from the tertiary service at 
Nottingham University Hospitals NHS Trust. CF patients were approached in order of 
clinic or ward attendance to reduce recruitment bias. CF patients were not required 
to have a history of gastrointestinal symptoms or complications. Controls, who had 
no clinical evidence or suspicion of CF, were recruited by open advertisement in the 
Nottingham area and were matched to cases by age and gender. Participants were 
excluded at screening if they met the exclusion criteria (Supplementary protocol).  
Procedures 
Participants spent one day at the Sir Peter Mansfield Imaging Centre, Nottingham, 
UK. They fasted from 20:00h the previous evening, other than a glass of water for 
essential medicines. On the day before scanning, participants avoided strenuous 
exercise and food and drink known to have laxative effects or contain highly 
fermentable carbohydrates. Participants stopped taking any laxatives or anti-
diarrhoeals on the day of MRI scanning.  
Firstly, participants completed the PAC-SYM9 and CFAbd-Score10 questionnaires 
and then underwent a fasting MRI scan, followed by their first meal. Serial MRI 
scans were performed after the meal, at set intervals (Figure 1), giving 11 scans in 
total. After each scan, participants scored their degree of abdominal pain, bloating 
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and flatulence on a Likert scale ranging between 0 (not at all) and 3 
(severe/disabling), as used in the GSRS.19 A second meal was eaten after the scan 
at 240 minutes.   
 
Figure 1. MRI study day schedule. Test meals are set standardised meals given to each participant. “T” is the 
time related to when the first test meal was eaten. For example, T0 is the MRI scan taken at 0 minutes after the 
first meal was eaten.  Post-prandial MRI scans were performed immediately after the first test meal, then at 30 
minute intervals for 180 minutes with further scans at 240, 300 and 360 minutes. The second test meal was given 
immediately after the T240 scan.   
No food or drink was permitted during the scan day other than the meals provided. 
The first meal (519 kcal, fat 19 g, carbohydrate 77g) consisted of 300 g creamed rice 
pudding mixed with 25 g seedless raspberry jam and 30 g double cream, and a drink 
of 100 mL orange juice with 240 mL water (all Sainsbury’s®, UK). The second meal 
(1,110 kcal, fat 54 g, carbohydrate 116 g) consisted of 400 g macaroni cheese 
(Sainsbury’s®, UK), 100 g strawberry cheesecake (Rhokett®, UK) and 240 mL water. 
Participants with CF took their prescribed pancreatic enzyme replacement therapy 
with meals.  
Scanning protocol  
A 3T Philips Ingenia MRI scanner (Philips Healthcare, Best, The Netherlands) was 
used. Participants were positioned supine with the DS anterior coil over the 
abdomen. A plastic guard held the coil away from the participant’s chest to allow for 
optimal breathing and a respiratory belt was used to monitor breathing patterns. An 
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initial survey scan determined the location of abdominal organs, followed by these 
sequences (see also supplementary MRI protocol):  
1) Identifying OCTT and measure colonic volumes: dual fast field gradient echo 
sequence.  
2) Aiding identification of the head of the meal at the caecum for OCTT analysis: 
high resolution balanced turbo field echo sequence.  
3) Assessing gastric volumes: half Fourier turbo spin echo sequence.  
4) Assessing SBWC: strongly T2-weighted turbo spin echo sequence.  
All sequences required a series of breath holds, with the maximum breath hold time 
of 10 s, and acquired at 11 time points throughout the day (Figure 1). Participants 
spent up to 15 minutes inside the magnet for each time point and spent the rest of 
the study day upright in an adjacent room.  
Data analysis 
MRI analyses were performed using Medical Image Processing, Analysis and 
Visualisation (MIPAV, NIH, Bethesda)20 and in-house software written in IDL® 6.4 
(Research Systems Inc. Boulder, Colorado, USA). MRI data were relabelled by an 
independent researcher to ensure blinding to participants’ group during MRI 
analyses.  
Outcome measures 
The primary outcome measure was OCTT, defined by the scan time when the meal 
was first detectable in the caecum (Supplementary figure 1).15 OCTTs were analysed 
by two researchers, with review by a third researcher to resolve any disagreements.  
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Secondary outcomes included: SBWC corrected for body surface area (area under 
the curve, AUC); colonic volume corrected for body surface area (AUC); gastric 
volumes for gastric half-emptying time; and gastrointestinal symptom scores. Body 
surface area was calculated using Mosteller’s formula (√ [(height (cm) x weight 
(kg))/3600]).21 
Gastric13 and colonic volumes16 were determined as described previously by using 
MIPAV. Gastric volumes were measured at each scanning time point until the 
second meal (Figure 1). Time taken for the stomach to half-empty was calculated 
(gastric half-emptying time) from sequential volumes, until the volume dropped below 
100 mL.13 
Colonic volumes were determined for ascending, transverse, descending and recto-
sigmoid segments.16 Where segments were fully collapsed and not visualised on 
MIPAV, a volume of 0 mL was assigned. A random 10% of scans were reviewed by 
a second researcher. The limit of inter-observer variability was no more than 5%, in 
keeping with previous data.17  
SBWC was analysed using in-house software as previously described.14 Corrected 
colonic volume and corrected SBWC were calculated by the colonic volume or 
SBWC AUC over the scan time period divided by the body surface area.  
CFAbd-Score10 and PAC-SYM9 questionnaires assessed gastrointestinal symptoms 
over the 2 weeks (low scores correlate with low symptom burden) preceding the 
scan day. Total CFAbd-Score10 and PAC-SYM9 score were calculated as previously 
described.  
Symptom scores after each MRI time point were calculated from the sum of Likert 
scale component scores for abdominal pain, bloating and flatulence.19 
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Statistical analysis  
Little prior data to base a power calculation were available so an informative pilot 
sample size was chosen. For OCTT, Kaplan-Meier curve and Log rank test were 
used. Non-parametric analyses (Wilcoxon signed-rank test) were planned for the 
secondary outcomes because of the matched study design and small sample size. 
Statistical analysis was carried out using RStudio, Inc (version 1.1.463, Boston). A p-
value of less than 0.05 was considered significant. 
Ethical Considerations 
Approval was obtained from the UK National Research Ethics Committee 
(18/WM/0242). All participants gave written informed consent. Participants under 16 
years gave written assent and parental consent. The study was registered on a 
publicly accessible trials database prior to commencement (ClinicalTrials.gov 




All procedures took place between August 2018 and February 2019. Fifty-one CF 
patients were eligible. CF patients were approached in order of their hospital 
attendance and the first 12 to provide written consent were enrolled into the study. 
Thirteen declined to participate and 2 withdrew consent as they did not like the 
standardised meals or MRI. None of the participants with CF had previous gut 
surgery and 1 had previous history of DIOS. Twelve age and gender-matched 
controls were also enrolled.  
Twelve CF patients and 12 controls completed the protocol without any adverse 
events. One further control participant was withdrawn and replaced as the participant 
was unable to complete the first standardised meal and the remaining 10 MRI scans.  
Although participants were age and gender matched, controls had a higher body 
weight than CF patients, reflecting the nutritional challenges in CF patients (Table 1). 
Median  






Age, years  19 (15, 25) 19 (15, 24) 0.42 
Male, n (%) 7 (58) 7 (58)  
Weight, kg  62 (59, 75) 56 (53, 59) 0.005 
Height, cm 166 (160, 176) 166 (158, 175) 0.33 
Table 1. Baseline characteristics for control and CF groups at the time of MRI scanning. 
Primary Outcome  
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Oro-Caecal Transit Time (OCTT) 
OCTT was significantly longer in CF than controls, with a median difference of 2 
hours (CF 330 mins [IQR 270, >360] vs. controls 210 mins [IQR 173, 315], p = 0.04). 
An OCTT above 360 minutes was not quantified as the last MRI scan was at 360 
minutes postprandial. The meal had not reached the caecum in 4 CF patients, 
confirmed by a high intensity signal in the small bowel at 360 minutes; suggesting an 
OCTT greater than 360 minutes. All controls had an OCTT of 360 minutes or less.  
Secondary outcomes 
Gastric half-emptying time 
There was no difference in median gastric half-emptying times (CF 97 minutes [IQR 
71, 128] vs. controls 80 minutes [IQR 66, 88], p = 0.3, Wilcoxon).  
Corrected Small Bowel Water Content (SBWC) 
Median corrected SBWC AUC was higher in CF than controls. This was contrary to 
our a priori hypothesis. There was no difference in median baseline corrected SBWC 
(CF 135 mL/m2 [IQR 90, 145] vs. controls 102 mL/m2 [IQR 65, 120], p = 0.73, 
Wilcoxon). However, the median corrected SBWC AUC was higher in CF (CF 62 





Figure 2. Corrected SBWC at each scanning time point for control and CF group. Error bars show median and 
IQR. Between 240 and 300 minutes, the drop in corrected SBWC (postprandial change in corrected SBWC) is 
reduced in the CF group compared to the control group. 
The large drop in corrected SBWC after the second meal (T240 to T300 scans) seen 
in the control group was not observed in the CF group. Exploratory analysis showed 
only minimal decrease in median corrected SBWC in the CF group (CF 13 mL/m2 
[IQR -13, 57] vs. controls 102 mL/m2 [IQR 67, 108], p = 0.002, Wilcoxon).  
Corrected Colonic Volumes 
No difference in median corrected baseline total colonic volumes was seen (CF 541 
mL/m2 [IQR 454, 688] vs. controls 387 mL/m2 [IQR 351, 482], p = 0.092, Wilcoxon). 
The baseline recto-sigmoid colonic volume for one control was not visualised and so 
was assigned 0 mL. There was a median difference of 63 L.min/m2 in corrected total 
colonic volume AUC between the two groups (CF 186 L.min/m2 [IQR 166, 206] vs. 
controls 123 L.min/m2 [IQR 89, 146], p = 0.012, Wilcoxon, Figure 3, Supplementary 
table 1). The transverse colonic volume at T360 for one control and recto-sigmoid 
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colonic volume at 6 time-points for another control were not visualised and so were  
assigned 0 mL.  
 
 
Figure 3. Box and whisker plot indicating the median, IQR and outliers of the corrected total colon volumes (AUC) 
for the control and CF group. 
Symptoms 
CFAbd-Score  
Median total CFAbd-Score tended to be higher in CF, but this was not statistically 
significant (CF 16 [IQR 5, 25] vs. controls 7 [IQR 3, 14], p=0.13, Wilcoxon). There 
was no correlation between the CFAbd-Score and primary or secondary MRI 
outcomes. The domains pain, disorders of bowel movement and impairment of 
quality of life scored numerically higher in the CF group but this was not statistically 




Figure 4. Median domain scores for CFAbd-Score between control and CF group 
PAC-SYM  
No difference in median PAC-SYM score was seen (CF 5 [IQR 2, 7] vs. control 4 
[IQR 1, 7], p=1, Wilcoxon), nor were there any correlations with MRI metrics.  
Likert scale for flatulence, bloating and abdominal pain  
Individual symptom scores and total scores using the Likert scale were low for both 
groups during the study day and not significantly different.  
Exploratory outcome 
Qualitative observation of the MR images identified appearances consistent with 
faecal material (usually seen in the large bowel) within the distal small bowel of CF 
patients. It was not seen in healthy controls or previously in similar studies 





















Our study has shown, for the first time, that MRI can elucidate gut function and 
transit in CF. We demonstrated a prolonged OCTT in the CF group, as well as an 
increase in both corrected SBWC and corrected colonic volume compared to 
matched controls.  
Our observation that OCTT is significantly longer in CF, whilst gastric half-emptying 
time is similar to controls, suggests that the delay in OCTT occurs in the small bowel 
and not the stomach. This is consistent with a previous report using the wireless 
motility capsule (SmartPill®).18 Transit time in the control group was similar to a 
previous study of healthy individuals using MRI.15 Our method assesses the normal 
physiological process by tracking the arrival of food in the caecum. This non-invasive 
observation contrasts with the SmartPill® which, due to its size, only leaves the 
stomach when propelled by a migrating motor complex and in association with 
gastric sieving.18,22 Gastric sieving refers to the separation of aqueous and solid   
components of a meal and the two components are expelled from the stomach at 
different rates; the larger the particle, the slower the emptying.23,24 
European guidelines11 for DIOS in CF recommend the osmotic laxative polyethylene 
glycol (PEG) as first line treatment, although no randomised controlled trials have 
tested this approach. Treatment with PEG is consistent with the principle of hydrating 
viscous secretions and correcting reduced intestinal water content. 
Contrary to our expectations, we observed a higher corrected SBWC AUC in CF. 
Higher SBWC volumes suggest an altered balance between intestinal secretion, 
absorption and motility. One plausible hypothesis would be that people with CF have 
an impaired capacity to absorb intestinal water because of their hyper-viscous 
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epithelial mucus.25 However, the combination of increased SBWC and prolonged 
OCTT could be explained by two mechanisms: a disrupted gastro-ileal reflex and 
exaggerated ileal brake.  
We observed a fall in SBWC following a second meal in the controls, in line with our 
previous MRI work.26 This is due to the gastro-ileal reflex where ileal contents are 
discharged into the colon on the arrival of calorific material in the stomach.27 The 
drop was markedly reduced in the CF group which may reflect restricted flow at the 
terminal ileum, a recognised site of pathology in CF.11 The images which suggest 
faecal material in the terminal ileum support this interpretation. 
The second possible mechanism is an exaggerated ileal brake, where ileal fat delays 
jejunal transit.28 Inadequate pancreatic enzymes could increase fat in the terminal 
ileum and release gut-derived peptide YY and glucagon-like peptide-1 hormone.28  
This would further slow expulsion of small bowel contents into the caecum.  
Both mechanisms raise questions about current treatment options for DIOS and the 
possibility that sub-clinical terminal ileum pathology exists. Stasis and prolonged 
transit times in the small bowel may lead to bacterial overgrowth and inflammation.12  
Increases in colonic volumes in our CF group could reflect the increased prevalence 
of constipation as a similar increase is found in functional constipation with slow 
transit.17 Our raw colonic volume data (Supplementary table 2, Supplementary table 
3) are consistent with other studies for healthy controls16 and constipation groups.17 
The gastrointestinal tract continues to develop and grow until adulthood.29 Although 
we matched the study groups for age and gender, we expected differences in 
nutritional status.2,3 Previous studies have described increasing colonic volumes with 
height16 and total intestinal length with height and weight.30 Correcting data by body 
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surface area, rather than body mass index, is a recognised approach in paediatric 
care, such as to determine appropriate drug doses31 and estimate glomerular 
filtration rates.32 We therefore opted to adjust SBWC and colonic volumes by body 
surface area.  
We assessed gastrointestinal symptoms as recent studies have shown significant 
differences between CF and control groups.10 This was not evident in our study and 
may be because we excluded people with previous extensive gut surgery and unable 
to stop drugs affecting bowel habit. It may also reflect the small sample size; since 
studies demonstrating a difference in gastrointestinal symptoms generally require 
larger sample sizes.5,6,9,10 Our study illustrates objective markers of CF gut function 
may be more sensitive in detecting an abnormality than subjective symptom report.  
Strengths and weaknesses 
Our completely non-invasive and radiation-free imaging technique allows a better 
understanding of the mechanism of disease in the undisturbed gastrointestinal tract. 
Despite concomitant lung disease, CF patients tolerated multiple breath-holds.  
We have captured the dynamic changes of the CF gastrointestinal tract. Such a 
protocol is, however, time consuming and costly; and this may limit widespread 
uptake. Future research using MRI should refine protocols to aid implementation in 
clinical practice. In comparison, the wireless motility capsule can measure only 
transit and not luminal volumes. However these systems cost much less than MRI 
and do not require the patient to spend many hours in the research facility.   
Another limitation is the need for a trained researcher to analyse OCTT. Future 
studies could use a less labour-intensive protocol to measure OCTT by employing 
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emerging MRI tools, such as indigestible MRI-visible mini-capsules which leave the 
stomach in the same phase as food particles during physiological gastric emptying 
and are more readily detectable in the intestine.24 
Future directions 
Future MRI studies should compare individuals with CF who have known 
gastrointestinal pathology with those who report minimal symptoms, to further 
explore the spectrum of CF gut pathophysiology. The same approach can then be 
applied to evaluating therapies for gastrointestinal symptoms or complications. MRI 
metrics may allow the evaluation of gastrointestinal effects of new CFTR modulator 
therapies.   
Conclusions  
This is the first study to demonstrate that investigating underlying gut pathologies in 
CF, using MRI, is achievable.  
Our methodology has provided a platform for studying CF gut disease and 
demonstrated the potential mechanisms of underlying CF gut pathology. We have 
identified novel areas for future research on gut function in CF, in particular the 
reduced postprandial drop in SBWC which could reflect terminal ileum obstruction.  
Further collaboration between the gastroenterology and CF communities are 
required to improve treatment and quality of life for CF patients.  
 21 
Acknowledgements 
We would like to acknowledge all our study participants, Nottingham University 
Hospitals NHS Trust and the Sir Peter Mansfield Imaging Centre, whom without, this 
study would not be completed.  
Conflict of Interest Statement 
NSD, CLD, LM, LB, HLB, AJ, PG have nothing to disclose. 
CN, JGM and GM report grants and speaker honorarium from Vertex, outside the 
submitted work. 
APP reports grants from Thrasher Research Fund, grants from Action for A-T, grants 
from Health Education East Midlands, outside the submitted work; these grants are 
for the development of lung MRI in children and infants.   
RS reports grants from Zespri International Ltd and Sanofi-Aventis, as well as 
lecturing fees from Menarini and Alfawasserman, outside the submitted work. 
ARS reports grants from Vertex, as well as speaker honoraria and expenses from 
Teva and Novartis and personal fees from Vertex, outside the submitted work.  In 
addition, ARS has a patent issued “Alkyl quinolones as biomarkers of Pseudomonas 
aeruginosa infection and uses thereof”. 
Funding 
Funding for the Gut Imaging for Function and Transit in CF (GIFT-CF) study was 
received from the Cystic Fibrosis Trust (VIA 061), Cystic Fibrosis Foundation 
(Clinical Pilot and Feasibility Award SMYTH18A0-I) and National Institute for Health 
Research Nottingham Biomedical Research Centre. 
 22 
References 
1. Elborn JS. Cystic fibrosis. Lancet 2016; 388: 2519-31. 
2. Cystic Fibrosis Foundation. Patient registry annual report. 2018. 
3. UK Cystic Fibrosis Registry. Annual data report 2018. 2019. 
4. Rowbotham NJ, Smith S, Leighton P, et al. The top 10 reserach priorities in cystic fibrosis 
developed by a partnership between people with CF and healthcare providers. Thorax 2018; 73: 388-
90. 
5. Hayee BH, Watson K-L, Campbell S, et al. A high prevalence of chronic gastrointestinal 
symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. 
United European Gastroenterol J 2019; 7(7): 881-8. 
6. Tabori H, Arnold C, Jaudszus A, et al. Abdominal symptoms in cystic fibrosis and their 
relation to genotype, history, clinical and laboratory findings. PLoS One 2017; 12(5): e0174463. 
7. van der Doef HP, Kokke FT, Beek FJ, et al. Constipation in pediatric cystic fibrosis patients: an 
underestimated medical condition. J Cyst Fibros 2010; 9(1): 59-63. 
8. Goss CH, Freeman AJ, Moshiree B, et al. Multicenter study of patient-reported 
gastrointestinal symptoms in people with cystic fibrosis (GALAXY). 2019. 
https://clinicaltrials.gov/ct2/show/NCT03801993?term=NCT03801993&rank=1 (last accessed 16th 
January 2020). 
9. Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom 
assessment questionnaire. Scand J Gastroenterol 1999; 9: 870-7. 
10. Jaudszus A, Zeman E, Jans T, et al. Validity and reliability of a novel multimodal questionnaire 
for the assessment of abdominal symptoms in people with cystic fibrosis (CFAbd-Score). Patient 
2019; 12(4): 419-28. 
11. Abraham JM, Taylor CJ. Cystic fibrosis & disorders of the large intestine: DIOS, constipation, 
and colorectal cancer. J Cyst Fibros 2017; 16 Suppl 2: S40-S9. 
12. Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the 
cystic fibrosis intestine. J Cyst Fibros 2017; 16 Suppl 2: S14-S23. 
13. Parker HL, Tucker E, Hoad CL, et al. Development and validation of a large, modular test 
meal with liquid and solid components for assessment of gastric motor and sensory function by non-
invasive imaging. Neurogastroenterol Motil 2016; 28(4): 554-68. 
14. Hoad CL, Marciani L, Foley S, et al. Non-invasive quantification of small bowel water content 
by MRI: a validation study. Phys Med Biol 2007; 52(23): 6909-22. 
15. Chaddock G, Lam C, Hoad CL, et al. Novel MRI tests of orocecal transit time and whole gut 
transit time: studies in normal subjects. Neurogastroenterol Motil 2014; 26(2): 205-14. 
16. Pritchard SE, Marciani L, Garsed KC, et al. Fasting and postprandial volumes of the 
undisturbed colon: normal values and changes in diarrhea-predominant irritable bowel syndrome 
measured using serial MRI. Neurogastroenterol Motil 2014; 26(1): 124-30. 
17. Lam C, Chaddock G, Marciani L, et al. Colonic response to laxative ingestion as assessed by 
MRI differs in constipated irritable bowel syndrome compared to functional constipation. 
Neurogastroenterol Motil 2016; 28(6): 861-70. 
18. Gelfond D, Ma C, Semler J, et al. Intestinal pH and gastrointestinal transit profiles in cystic 
fibrosis patients measured by wireless motility capsule. Dig Dis Sci 2013; 58(8): 2275-81. 
19. Svedlund J, Sjödin I, Dotevall G. GSRS -- a clinical rating scale for gastrointestinal symptoms 
in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33(2): 129-34. 
20. National Institutes of Health. About MIPAV. 2019. https://mipav.cit.nih.gov (last accessed 17 
December 2019). 
21. El Edelbi R, Lindemalm S, Eksborg S. Estimation of body surface area in various childhood 
ages--validation of the Mosteller formula. Acta Paediatr 2012; 101(5): 540-4. 
 23 
22. Marciani L, Pritchard SE, Hellier-Woods C, et al. Delayed gastric emptying and reduced 
postprandial small bowel water content of equicaloric whole meal bread versus rice meals in healthy 
subjects: novel MRI insights. Eur J Clin Nutr 2013; 67(7): 754-8. 
23. Meyer JH, Thomson JB, Cohen MB, Shadchehr A, Mandiola SA. Sieving of solid food by the 
canine stomach and sieving after gastric surgery. Gastroenterology 1979; 76(4): 804-13. 
24. Spiller R, Marciani L. Intraluminal impact of food: new insights from MRI. Nutrients 2019; 
11(5). 
25. Russo MA, Hogenauer C, Coates SW, Jr., et al. Abnormal passive chloride absorption in cystic 
fibrosis jejunum functionally opposes the classic chloride secretory defect. J Clin Invest 2003; 112(1): 
118-25. 
26. Marciani L, Cox EF, Hoad CL, et al. Postprandial changes in small bowel water content in 
healthy subjects and patients with irritable bowel syndrome. Gastroenterology 2010; 138(2): 469-77, 
77 e1. 
27. Deiteren A, Camilleri M, Burton D, et al. Effect of meal ingestion on ileocolonic and colonic 
transit in health and irritable bowel syndrome. Dig Dis Sci 2010; 55(2): 384-91. 
28. Spiller R, Trotman IF, Adrian TE, et al. Further characterisation of the ileal brake reflex in man 
- effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of 
neurotensin, enteroglucagon, and peptide YY. Gut 1988; 29: 1042-51. 
29. Weaver LT, Austin S, Cole TJ. Small intestinal length - a factor essential for gut adaptation. 
Gut 1991; 32: 1321-3. 
30. Sadahiro S, Ohmura T, Yamada Y, et al. Analysis of length and surface area of each segment 
of the large intestine according to age, sex and physique. Surg Radiol Anat 1992; 14: 251-7. 
31. Sharkey I, Boddy AV, Wallace H, et al. Body surface area estimation in children using weight 
alone - application in paediatric oncology. Br J Cancer 2001; 85: 23-8. 
32. Counahan R, Chantler C, Ghazali S, Et al. Estimation of glomerular filtration rate from plasma 
creatinine concentration in children. Arch Dis Child 1976; 51: 875-8. 
 
